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The aim of this study was to examine the changes in hemostasis parameters in endocarditis and thromboembolic events
in nonfatal methicillin-sensitive Staphylococcus aureus bacteremia (MS-SAB) – a topic not evaluated previously. In
total, 155 patients were recruited and were categorized according to the presence of endocarditis or thromboembolic
events with gender-age adjusted controls. Patients who deceased within 90 days or patients not chosen as controls were
excluded. SAB management was supervised by an infectious disease specialist. Patients with endocarditis (N = 21),
compared to controls (N = 21), presented lower antithrombin III at day 4 (p < 0.05), elevated antithrombin III at day
90 (p < 0.01), prolonged activated partial thromboplastin time at days 4 and 10 (p < 0.05), and enhanced thrombin–an-
tithrombin complex at day 4 (p < 0.01). Thromboembolic events (N = 8), compared to controls (N = 34), significantly
increased thrombin–antithrombin complex at day 4 (p < 0.05). In receiver operating characteristic analysis, the changes
in these hemostasis parameters at day 4 predicted endocarditis and thromboembolic events (p < 0.05). No differences in
hemoglobin, thrombocyte, prothrombin fragment, thrombin time, factor VIII, D-dimer or fibrinogen levels were
observed between cases and controls. The results suggest that nonfatal MS-SAB patients present marginal hemostasis
parameter changes that, however, may have predictability for endocarditis or thromboembolic events. Larger studies
are needed to further assess the connection of hemostasis to complications in SAB.
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thromboembolic events.
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Staphylococcus aureus is a major cause of severe bac-
teremia, and Staphylococcus aureus bacteremia (SAB)
is associated with mortality reaching 15%–30%
(1–3). Management guided by infectious special-
ists and non-delayed proper antimicrobial treatment
improve outcome (4–6). Endocarditis and throm-
boembolic events are feared complications associ-
ated with negative prognostic impact. Studies
report endocarditis in 4%–20% of SAB patients
(1–5) and thromboembolic events due to endocardi-
tis in 47%–61% of SAB patients (7, 8). Throm-
boembolic events are explained by fragmentation of
infective vegetation by blood turbulence (9) and vir-
ulence factor of S. aureus (e.g. coagulase) promot-
ing the coagulation (10). Thromboembolic events,
however, are not uncommon in systemic bacterial
infections regardless of endocarditis (11–16).
Severe infections and subsequent inflammatory
processes may induce hemostatic alterations rang-
ing from coagulation activation to thromboembolic
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events and life-threatening conditions, for example
disseminated intravascular coagulation (17–21).
Studies have observed that disturbed hemostatic
mechanisms include procoagulant upregulation,
physiological anticoagulant downregulation and fib-
rinolysis suppression (22–24). These results in
increased concentrations of acute phase protein fib-
rinogen and factor VIII (17, 19), prothrombin frag-
ments and thrombin–antithrombin complexes (20,
21) and D-dimer ((18, 25)), but decreased natural
anticoagulant antithrombin III (17, 26). Further-
more, in vitro studies have shown that bacterial
structures, for example peptidoglycan may activate
platelets and induce coagulation (27–29). However,
although endocarditis and thromboembolic events
occur in SAB, systematic studies of hemostasis
parameters have not been done previously.
The objective here was to prospectively evaluate
hemostasis parameter changes in nonfatal methi-
cillin-sensitive (MS) SAB in two major thrombo-
genic states, endocarditis or thromboembolic
events, and compare them with gender-age adjusted
control patients with MS-SAB. A formal infectious
disease specialist guidance guaranteed proper clini-
cal management. The inclusion of only MS-SAB
cases enabled a study setting where each patient
received correct antibiotic therapy from the first
day of positive blood culture thus avoiding distur-
bance from variations in empiric antibiotic therapy.
MATERIALS AND METHODS
Settings and study population
The study prospectively enrolled adult patients with at
least one blood culture positive for MS S. aureus at Hel-
sinki University Central Hospital during January 1999 to
May 1999 and January 2000 to August 2002. Patients with
endocarditis or thromboembolic events were identified
together with gender-age adjusted control patients without
endocarditis or a thromboembolic event. Patients were
divided into two groups, the endocarditis group and the
thromboembolic events group, and both groups included
gender-age adjusted controls and were followed up for
90 days. All patients received formal bedside infectious
disease specialist consultation to ensure proper manage-
ment of SAB. Data recording included age, gender, infec-
tion acquisition, previous hospitalizations, underlying
diseases with focus on risk factors for endocarditis and
thromboembolic events, foreign devices, medication pre-
ceding bacteremia, illness severity including intensive care
unit (ICU) treatment and length and administration route
of antibiotic therapy. Infection foci and thromboembolic
events were diagnosed through radiological, bacteriologi-
cal or pathological investigations. Laboratory results,
including 10 different hemostasis parameters, were
recorded repeatedly during the 90-day follow-up time. The
decision to analyze hemostasis parameters was made on
day 90 when it was evident that the patient had survived
90-day follow-up time and could have hemostasis
parameters analyzed (from stored blood samples) through-
out the whole follow-up time. Hence, patients who died
during the 90-day follow-up were excluded. Further exclu-
sion criteria were age <18 years, pregnancy, breast-feeding,
bacteremia 28 days prior to study or neutropenia
(<0.5 9 109/L). No methicillin-resistant SAB was
accepted. The trial was approved by The Institutional
Review Board of Helsinki University Central Hospital
and The Ethical Committee of Helsinki University Central
Hospital. A written informed consent was provided by
each patient.
Definitions
We classified the severity of background diseases accord-
ing to McCabe0s criteria (30). The modified Duke criteria
were applied for endocarditis (31). Sepsis with hypoten-
sion, hypoperfusion or organ failure was defined as severe
sepsis, whereas sepsis with arterial hypotension not
responding to adequate fluid resuscitation was defined as
septic shock (32). The definition of deep infection foci
included pneumonia, osteomyelitis, septic arthritis, deep-
seated abscess and foreign body infections. Both arterial
(myocardial infarction, unstable angina pectoris, stroke,
transient ischemic attack and parenchymal embolizations,
e.g. splenic thromboembolism) and venous (deep vein
thrombosis or pulmonary embolism) complications were
recorded.
Blood hemostasis parameters
We recorded hemostasis parameters at three time-points.
The median time phase between blood culture collection
and reporting of bacteremia pathogen is commonly
3 days. Thus, we decided to record hemostasis parameters
at day 4 (i.e. 1-day past positive blood culture report), at
day 10 and day 90. Parameters included; (i) prothrombin
fragments 1 + 2, (ii) thrombin–antithrombin complex, (iii)
factor VIII, (iv) D-dimer, (v) fibrinogen, (vi) antithrombin
III, (vii) thrombin time, (viii) activated partial thrombo-
plastin time (APTT), (ix) hemoglobin and (x) thrombocyte
levels. Laboratory tests were always collected at 07.00 am.
An explicit laboratory methodology has been described
previously (33).
Anticoagulation
The decision to commence anticoagulation therapy and
the choice of medication and dosage were made by a
senior internal medicine specialist in cooperation with the
infectious disease specialist. The anticoagulant used was
either warfarin or the low-molecular-weight heparin
enoxaparine. Warfarin was administered (3 or 5 mg) once
a day (at 08.00 am) and the dosage was titrated until an
international normalized ratio (INR) of 2–3 was achieved.
The INR reference of 2–3 was considered appropriate.
The dosage of enoxaparine was 1 mg/kg twice a day (at
08.00 am and at 22.00 pm).
Formal infectious specialist guidance
All patients received formal infectious disease specialist
consultation within 7 days of positive blood culture report
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including review of patient records, physical examination
and written instructions on clinical management. Detailed
information on consultations has been provided previously
(5).
Antibiotic therapy
The standard antibiotic therapy was a semisynthetic peni-
cillin, cloxacillin (2.0 g q 4 h) intravenously, alternatively
cefuroxime (1.5 g q 6 h), ceftriaxone (2.0 g q 24 h),
clindamycin (600 mg q 6–8 h), or vancomycin (1.0 g
b.i.d.) for patients with contradictions for penicillin. The
potential subsequent standard oral therapy was cloxacillin
(500 mg q 6 h), cephalexin or cefadroxil (500 mg q 6 h),
or clindamycin (300 mg q 6 h). Fluoroquinolone (levoflox-
acin) or rifampicin served as an additional antibiotic ther-
apy. The dose of levofloxacin was 500 mg (intravenously
or orally) once daily for patients under 60 kg and 500 mg
b.i.d. for patients over 60 kg in weight. Rifampicin was
administered 450 mg (orally or intravenously) once daily
for patients under 50 kg and 600 mg once daily for
Fig. 1. Study profile. Two groups each including 42 methicillin-sensitive Staphylococcus aureus bacteremia (SAB) patients.
Hemostasis laboratory parameters were determined at days 4, 10 and 90. Patients with infective endocarditis or throm-
boembolic events were compared to gender-age adjusted controls patients without endocarditis or thromboembolic events.
The management of SAB was overseen by infectious disease specialist at all times. Patients were followed up for 90 days.
(1) According to modified Dukes criteria for endocarditis (31). (2) Myocardial infarction, unstable angina pectoris, stroke,
transient ischemic attack, parenchymal embolization (e.g. splenic thromboembolism), deep vein thrombosis or pulmonary
embolism. (3) Hemostasis parameters that is hemoglobin, thrombocytes, prothrombin fragments 1 + 2, thrombin–an-
tithrombin complex, factor VIII, D-dimer, activated partial thromboplastin time, fibrinogen, antithrombin III and throm-
bin time.
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patients over 50 kg in weight. The proper length of ther-
apy was defined as intravenous administration for at least
28 days for deep infection focus and at least 14 days in
the absence of deep infection. Rifampicin was adminis-
tered when there was a suspicion or diagnosis of deep
infection foci. Detailed information on antibiotic
Table 1. Methicillin-sensitive S. aureus bacteremia patients categorized according to endocarditis or thromboembolic event
Infective endocarditis Thromboembolic events
Variables Present
(N = 21)
Absent31
(N = 21)
OR
(95% CI)
p-value Present
(N = 8)
Absent31
(N = 34)
OR
(95% CI)
p-value
Demographics
Male sex 14 (67) 14 (67) 1.00 (0.28–3.61) NS 5 (63) 23 (68) 0.80 (0.16–3.95) NS
Age > 60 years 6 (29) 4 (19) 1.70 (0.40–7.20) NS 2 (25) 8 (24) 1.08 (0.18–6.46) NS
Weight (kg)
Mean ( SD) 69  12 79  15 — NS 71  12 75  15 — NS
BMI 23  3.8 27  5.3 — NS 23  3.0 25  5.3 — NS
Nosocomial infection 8 (38) 12 (57) 0.46 (0.13–1.59) NS 1 (13) 19 (56) 0.11 (0.01–1.02 <0.05
Previous hospitalization42 8 (38) 12 (57) 0.46 (0.13–1.59) NS 1 (13) 19 (56) 0.11 (0.01–1.02 <0.05
Underlying conditions
Healthy-nonfatal53 15 (71) 18 (86) 0.42 (0.09–1.96) NS 6 (75) 27 (79) 0.78 (0.13–4.72) NS
Ultimately rapidly fatal53 6 (29) 3 (14) 2.40 (0.51–11.3) NS 2 (25) 7 (21) 1.29 (0.21–7.80) NS
Coronary heart disease 6 (29) 2 (10) 3.80 (0.67–21.6) NS 2 (25) 6 (18) 1.56 (0.25–9.67) NS
Chronic pulmonary disease 4 (19) 2 (10) 2.24 (0.36–13.8) NS 1 (13) 5 (15) 0.83 (0.08–8.27) NS
Chronic liver disease 11 (52) 5 (24) 3.52 (0.94–13.2) NS 5 (63) 11 (32) 3.49 (0.70–17.3) NS
Chron. renal failure 3 (14) 3 (14) 1.00 (0.18–5.63) NS 2 (25) 4 (12) 2.50 (0.37–16.9) NS
Diabetes mellitus 5 (24) 3 (14) 1.88 (0.39–9.12) NS 3 (38) 5 (15) 3.48 (0.63–19.4) NS
HIV positive 2 (10) 1 (5) 2.11 (0.18–25.2) NS 1 (13) 2 (6) 2.29 (0.18–28.8) NS
Predisposing factors64
Hypertension 5 (24) 9 (43) 0.42 (0.11–1.57) NS 1 (13) 13 (38) 0.23 (0.03–2.09) NS
Heart arrhythmia75 5 (24) 1 (5) 6.25 (0.66–59.0) NS 1 (13) 5 (15) 0.83 (0.08–8.27) NS
Injective drug use 11 (52) 5 (24) 3.52 (0.94–13.2) NS 5 (63) 11 (32) 3.49 (0.70–17.3) NS
Previous ACH/Stroke 1 (5) 3 (14) 0.86(0.72–1.02) NS 1 (13) 3 (9) 0.91 (0.82–1.01) NS
Previous endocarditis 3 (14) 0 — NS 1 (13) 2 (6) 2.29 (0.18–28.9) NS
Foreign devices/bodies86
Any surgical procedure 6 (29) 2 (10) 3.80 (0.67–21.6) NS 3 (38) 5 (15) 3.48 (0.63–19.4) NS
Any foreign device/body 6 (29) 6 (29) 1.00 (0.26–3.82) NS 1 (13) 11 (32) 0.29 (0.03–2.74) NS
Central venous catheter 3 (14) 4 (19) 0.71(0.14–3.64) NS 1 (13) 6 (18) 0.79 (0.67–0.94) NS
Orthopedic device/body 1 (5) 2 (19) 0.48 (0.04–5.68) NS 1 (13) 2 (6) 2.29 (0.18–28.8) NS
Prosthetic heart valve 5 (24) 0 — <0.05 0 5 (15) — NS
Preceding medication42
Statin 2 (10) 3 (14) 0.63 (0.09–4.23) NS 0 5 (15) — NS
Aspirin 2 (10) 3 (14) 0.63 (0.09–4.23) NS 1 (13) 4 (12) 1.07 (0.10–11.1) NS
b-Blocker 8 (38) 5 (24) 1.97 (0.52–7.49) NS 2 (25) 11 (32) 0.69 (0.12–4.03) NS
Corticosteroid 12 (57) 7 (33) 2.68 (0.76–9.34) NS 5 (63) 14 (41) 2.38 (0.49–11.6) NS
Severity of illness
Septic shock97 0 0 — — 0 0 — —
ICU97 7 (33) 1 (5) 10.0 (1.10–90.6) <0.05 2 (25) 6 (18) 1.56 (0.25–9.67) NS
ICU108 12 (57) 1 (5) 26.6 (2.99–237) <0.001 2 (25) 6 (18) 1.56 (0.25–9.67) NS
ICU mean (days  SD)108 2.57  3.2 0.1  0.2 — <0.001 3.3  3.9 0.85  2.0 — NS
Deep infection foci108
Pneumonia 14 (67) 8 (38) 3.25 (0.92–11.5) NS 7 (88) 15 (44) 8.87 (0.98–80.1) <0.05
Deep abscesses 13 (62) 11 (52) 1.48 (0.43–5.05) NS 5 (63) 19 (56) 1.32 (0.27–6.41) NS
Osteomyelitis—septic arthritis 11 (52) 6 (29) 2.75 (0.77–9.86) NS 4 (50) 13 (38) 1.62 (0.34–7.60) NS
Foreign body infection 8 (38) 2 (10) 5.85 (1.07–32.1) <0.05 2 (25) 8 (24) 1.08 (0.18–6.46) NS
Endocarditis subgroup
Left-sided native 5 (24) 0 — — — — — —
Right-sided native 8 (38) 0 — — — — — —
Prosthetic valve 8 (38) 0 — — — — — —
Antibiotic/anticoagulation
Antistaphylococcal
penicillin119
17 (81) 11 (52) 3.86 (0.97–15.4) NS 7 (88) 21 (62) 4.33 (0.48–39.4) NS
Cephalosporin119,1210 3 (15) 7 (33) 0.33 (0.07–1.53) NS 1 (12) 9 (26) 0.39 (0.04–3.69) NS
Clindamycin119 0 1 (5) — NS 0 1 (3) — NS
Vancomycin119 1 (5) 2 (10) 0.48 (0.04–5.68) NS 0 3 (9) — NS
Fluoroquinolone1311 10 (48) 10 (48) 1.00 (0.29–3.36) NS 5 (63) 15 (44) 2.11 (0.43–10.3) NS
Rifampicin1311 14 (67) 11 (52) 1.82 (0.52–6.33) NS 6 (75) 19 (56) 2.37 (0.42–13.5) NS
Monotherapy1412 5 (24) 7 (33) 1.60 (0.41–6.19) NS 1 (12) 11 (32) 3.35 (0.37–30.7) NS
Combination therapy1513 16 (76) 14 (67) 1.60 (0.41–6.19) NS 7 (88) 23 (68) 3.35 (0.37–30.7) NS
Anticoagulation1614,1715 19 (90) 8 (38) 15.4 (2.81–84.7) <0.001 6 (75) 21 (62) 1.86 (0.33–10.6) NS
LWMH 11 (52) 8 (38) 1.79 (0.52–6.11) NS 5 (63) 14 (41) 2.38 (0.49–11.6) NS
Warfarin 8 (38) 0 — — 1 (13) 7 (21) 0.55 (0.06–5.25) NS
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indications and administration have been provided previ-
ously (34, 35).
Statistical analysis
Pearson’s chi-squared test was applied for categorical
variables and Mann–Whitney U test for continuous vari-
ables. Univariate analyses and odds ratios (ORs) with
95% confidence intervals (CIs) were calculated. Receiv-
ing operating characteristic (ROC) analyses were used to
evaluate the discriminative power of hemostasis parame-
ters at an early phase in predicting endocarditis or
thromboembolic events. The area under the curve
(AUC) was calculated. Modified power analyses, observ-
ing power coefficients and 95% CIs, were applied to
estimate the reliability of the patient participant number.
A professional statistician was consulted for all analyses.
Tests were two-tailed and p < 0.05 was considered sig-
nificant. Analyses were performed with SPSS 12.0 (SPSS
Inc. Chicago, IL, USA).
RESULTS
The patient cohort
Altogether 155 patients were enrolled. Two groups
were designed including 21 patients with SAB and
endocarditis (endocarditis group) and 8 patients
with SAB and thromboembolic events (throm-
boembolic events group). Gender-age adjusted
controls included 21 and 34 patients, respectively.
Patients who deceased within 90 days (N = 17)
and patients not chosen as gender-age adjusted
controls (N = 54) were excluded (Fig. 1). Patients
for both the groups were included in the chrono-
logic order they were encountered. Subgrouping of
the endocarditis patients included: five (24%) cases
of native left-sided endocarditis, eight cases (38%)
of native right-sided endocarditis and eight cases
(38%) of prosthetic valve endocarditis (Table 1).
There were altogether eight patients with arterial
or venous thromboembolic events recorded: one
case of unstable angina pectoris, five cases of
stroke, one case of splenic thromboembolism and
one case of deep vein thrombosis with subsequent
pulmonary embolism. No patients were lost during
the follow-up time of 90 days. The median time
between blood culture sampling and confirmation
of S. aureus growth was 3 days.
Demographics and underlying conditions
No differences in demographics, underlying condi-
tions, predisposing factors or medications preced-
ing SAB of patients with endocarditis or
thromboembolic events compared to gender-age
adjusted controls were observed (Table 1). How-
ever, patients with thromboembolic events had
less nosocomial SAB and previous hospitalization
compared to controls (p < 0.05), whereas pros-
thetic heart valve was more common in patients
with endocarditis compared to controls (p < 0.05;
Table 1).
Table 1. (continued)
Infective endocarditis Thromboembolic events
Variables Present
(N = 21)
Absent31
(N = 21)
OR
(95% CI)
p-value Present
(N = 8)
Absent31
(N = 34)
OR
(95% CI)
p-value
Outcome
Defervescense
Mean (days  SD)108 5.8  7.0 3.3  2.4 — <0.05 4.5  2.9 4.6  5.9 — NS
≥7 days 7 (33) 1 (5) 10.0 (1.10–90.6) <0.05 2 (25) 6 (18) 1.56 (0.25–9.67) NS
Hospital duration
(days  SD)108
47  15 30.4  16 — <0.01 49  13 36  18 — <0.05
ACH, acute cerebral hemorrhage; NS, nonsignificant; SD, standard deviation.
1Gender-age adjusted controls.
2Within preceding 3 months.
3According to McCabe0s classification (30).
4For endocarditis or thromboembolic events.
5Including atrial fibrillation.
6In one year.
7At blood cultures.
8Within 90-day follow-up.
9Standard antibiotic therapy.
10Cefuroxime or ceftriaxone.
11Additional therapy.
12Only standard antibiotic therapy.
13Standard and additional antibiotic therapy.
14Warfarin or low-weight-molecular heparin (LWMH).
15Initiated within days 1–7 of SAB diagnosis.
© 2019 APMIS. Published by John Wiley & Sons Ltd 519
HEMOSTASIS AND S. AUREUS BACTEREMIA
Severity of illness, deep infections and antimicrobial
therapy
Altogether 19% needed ICU treatment at blood
culture collection time-point, whereas 31% received
ICU treatment during the 90-day follow-up time.
The mean ICU duration was 1.3  2.8 days (SD)
(Table 1). There were no cases of septic shock dur-
ing the 90-day follow-up. Patients with endocarditis
were more likely to receive ICU treatment than
controls (33% vs 5%; p < 0.05), whereas no corre-
sponding trend was seen for patients with throm-
boembolic events (Table 1). The overall prevalence
of deep infection foci in the patient population was
83%. No differences in the occurrence of deep
abscess, osteomyelitis or septic arthritis were seen
between cases and controls. However, foreign body
infections were more common among patients with
endocarditis compared to controls (38% vs 10%,
p < 0.05). Patients with thromboembolic events suf-
fered more often from pneumonia compared to
controls (88% vs 44%, p < 0.05; Table 1). All
patients received an antimicrobial agent effective
in vitro against the S. aureus isolate starting from
the day of positive blood culture. Altogether 67%
received antistaphylococcal penicillin, 24% cepha-
losporin, whereas 7% were treated with van-
comycin and 2% with clindamycin. Rifampicin was
provided to 60% of patients, whereas fluoro-
quinolone (levofloxacin) was received by 48%
(Table 1). No differences in antimicrobial therapy
was seen between patients with or without endo-
carditis or thromboembolic events (Table 1).
Anticoagulation
Within the first week, 64% of patients had antico-
agulants initiated, whereas within the 90-day fol-
low-up 74% patients had received anticoagulants
(Table 1). Hence, among patients who received
anticoagulants, the majority had the anticoagulant
initiated within the first week, whereas for a minor-
ity the anticoagulant was commenced at a later
time-point. Low-molecular-weight heparin was
more frequently used than warfarin. Within the first
week, 70% received low-molecular-weight heparin
and 30% received warfarin. Patients with
Table 2. Hemostasis parameters in methicillin-sensitive S. aureus bacteremia according to endocarditis or thromboembolic
event
Infective endocarditis Thromboembolic events
Hemostasis19 parameters Normal ranges Present
(N = 21)
Absent20
(N = 21)
p-value Present
(N = 8)
Absent20
(N = 34)
p-value
Hemoglobin21 134–167 g/L 111  17 121  19 NS 124  15 114  19 NS
Thrombocytes21 150–360 9 109L 190  115 251  108 NS 155  94 235  115 NS
Prothrombin fragments
Day 4 0–0.35 nmol/L 1.47  0.7 1.9  1.4 NS 1.69  0.6 1.69  1.2 NS
Day 10 1.43  0.8 1.6  1.4 NS 1.77  1.1 1.48  1.2 NS
Thrombin–antithrombin complex
Day 4 <4 lg/L 6.30  2.4 4.5  2.2 <0.01 6.51  1.9 5.13  2.5 <0.05
Day 10 4.28  1.8 6.8  12 NS 3.79  1.7 5.98  9.5 NS
Factor VIII
Day 4 52–148% 193  48 203  79 NS 194  61 199  66 NS
Day 10 170  52 169  65 NS 174  73 168  56 NS
D-dimer
Day 4 < 0.5 mg/L 2.4  1.7 1.9  1.4 NS 1.99  1.9 2.20  1.5 NS
Day 10 2.2  1.9 1.9  1.6 NS 2.01  2.7 2.04  1.6 NS
Fibrinogen
Day 4 1.7–4.0 g/L 5.4  1.5 6.2  2.2 NS 5.16  1.3 5.91  1.9 NS
Day 10 5.4  1.2 5.2  1.6 NS 5.47  1.7 5.26  1.4 NS
Antithrombin III
Day 4 84–108% 89  16 104  20 <0.05 88.8  16 98.4  20 NS
Day 10 119  19 114  15 NS 126  22 115  16 NS
Thrombin time
Day 4 17–25 s 15  1.7 15.8  1.6 NS 14.8  1.4 15.6  1.7 NS
Day 10 17  3.3 17.1  2.5 NS 17.7  4.7 16.8  2.33 NS
Activated partial thromboplastin time
Day 4 23–33 s 40  6.3 36  3.9 <0.05 37.4  6.9 38.6  5.4 NS
Day 10 45  12 38  5.9 <0.05 48 .0  19 40.2  62 NS
NS, non-significant. Data are mean  SD. Values of p with Mann–Whitney U test.
1Hemostasis parameters at days 4 and 10 after diagnosis of methicillin-sensitive S. aureus bacteremia.
2Gender-age adjusted controls.
3Hemoglobin and thrombocyte values for day 4 only.
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endocarditis, compared to controls, received more
often anticoagulants (90% vs 38%, p < 0.001),
whereas no difference was seen between patients
with thromboembolic events and their controls
(75% vs 62%; Table 1).
Hemostasis parameters
Significant differences between endocarditis patients
and controls were found in thrombin–antithrombin
complex, antithrombin III and APTT levels (Table 2,
Figs 2–7aa–). Thrombin–antithrombin complex at
day 4 was higher in patients with endocarditis com-
pared to controls (6.3  2.4 vs 4.5  2.2 lg/L,
p < 0.01) and in patients with thromboembolic
events compared to those without it (6.5  1.9 vs
5.1  2.5 lg/L, p < 0.05). This difference was dimin-
ished by days 10 and 90 as the concentrations
increased in control patients (Table 2, Figs 2–7aa–).
The activity of antithrombin III at day 4 was lower
and at day 90 higher in patients with endocarditis
compared to controls (89  16 vs 104  20%,
p < 0.05 and 121  19 vs 107  12%, p < 0.01),
whereas no difference was observed in patients with
and without thromboembolic events. APTT was pro-
longed on days 4 and 10 in patients with endocarditis
compared to patients without (40  6.3 s vs
36  3.9 and 45  12 s vs 38  5.9 s, p < 0.05)
whereas no differences were observed at day 90.
However, when comparing patients with thromboem-
bolic events and controls, no differences were seen in
APTT (Table 2 and Figs 2–7bb–).
ROC analyses for significant hemostasis changes
were performed to evaluate their discriminative
power in predicting occurrence of endocarditis or
thromboembolic events. Hemostasis parameters
with predictable value for endocarditis were
antithrombin III at day 4 (AUC 0.71, 95% CI
0.54–0.86, p < 0.05), APTT at days 4 and 10 (AUC
0.69, 95% CI 0.53–0.87, p < 0.05 and AUC 0.70,
95% 0.54–0.87, p < 0.05) and thrombin–antithrom-
bin complex at day 4 (AUC 0.75, 95% CI 0.60–
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Fig. 2. Graphic presentation of the hemostasis parameters thrombin–antithrombin complex (2A–B), factor VIII (3A–B),
D-dimer (4A–B), fibrinogen (5A–B), antithrombin III (6A–B) and activated partial thromboplastin time (7A–B) for
patients with diagnosis of endocarditis (N = 21) vs gender-age adjusted controls patients (N = 21) or patients with
thromboembolic events (N = 8) vs gender-age adjusted controls patients (N = 34). Follow-up time of 90 days.
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0.91, p < 0.01). Thrombin–antithrombin complex at
day 4 was the only predictable value for throm-
boembolic events (AUC 0.74, 95% CI 0.58–0.89,
p < 0.05). Prothrombin fragment, thrombin time,
factor VIII, D-dimer or fibrinogen levels did not
predict endocarditis or thromboembolic events in
ROC analyses.
Additional analyses were performed to further
evaluate the hemostasis parameter fluctuations in
SAB. Patients were categorized according to (i)
ICU vs non-ICU treatment, (ii) antibiotic
monotherapy (standard antibiotic therapy only) vs
combination therapy (standard antibiotic therapy +
fluoroquinolone or rifampicin) or (iii) low
(<2.0 mg/L) vs high (>2.0 mg/L) D-dimer at day 4.
ICU patients, compared to non-ICU patients, had
lower thrombocyte count (p < 0.05) and lower
antithrombin III (p < 0.05) at day 4, whereas no
other hemostasis parameter changes were observed.
No differences in hemostasis parameters were
observed when we categorized the whole patient
cohort according to mono- or combination antibi-
otic therapy. Patients with low D-dimer, compared
to high D-dimer, had higher antithrombin III at
day 4 (p < 0.05) and higher activated partial
thromboplastin time at day 10 (p < 0.05) whereas
no other hemostasis parameter changes were
observed.
The mean observed power coefficient for
hemostasis parameters in the endocarditis group
was 0.48  0.29 (SD) and most of the 95% CIs
were narrow as compared to the width of normal
ranges for the hemostasis parameters. For hemosta-
sis parameters in the thromboembolic events group
the mean observed power coefficient was
0.14  0.09 (SD); however, most of the 95% CIS
were wide as compared to the normal ranges for
the hemostasis parameters.
Defervescence and hospitalization
The mean defervescense time was longer for
patients with endocarditis compared to controls
(5.8  7.0 vs 3.3  2.4 days, p < 0.05), whereas no
corresponding trend was seen for thromboembolic
events. The mean hospitalization was 38 days and
longer for patients with endocarditis or throm-
boembolic events as compared to controls (47  15
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Fig. 3. See Fig. 2 caption.
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vs 30  16, p < 0.01 and 49  13 vs 36  18 days,
p < 0.05 respectively).
DISCUSSION
This is the first study to report a systematic and
prospective evaluation of hemostasis parameter
changes and their association and predictability for
endocarditis and thromboembolic events in MS-
SAB. Patients with endocarditis, compared to age-
and gender-adjusted controls, presented an
increased hemostatic activity at an early time-point
with lowered levels of antithrombin III and elevated
levels of thrombin–antithrombin and prolonged
APTT. Patients with thromboembolic events, com-
pared to gender-age adjusted controls, had
increased levels of thrombin–antithrombin at an
early time-point. The early hemostasis parameter
changes also seemed to predict endocarditis or
thromboembolic events. However, no cases of sep-
tic shock were present, all patients were supervised
by an infectious disease specialist including non-de-
layed proper antimicrobial therapy initiation and
deceased patients were excluded. These results sug-
gest the possibility that proper clinical management
among surviving MS-SAB patients result in rapid
decline of bacterial load, reduced inflammation
activity and lower systemic coagulation activation.
This may further explain similarities in other
hemostasis parameters between the groups, and
why some hemostasis parameters did not differ
between patients with endocarditis or thromboem-
bolic events as compared to gender-age adjusted
controls.
The hemostasis parameters evaluated in previous
reports on endocarditis and subsequent throm-
boembolic events have been prothrombin frag-
ments, a side product of prothrombin to thrombin
conversion, and thrombin–antithrombin complex, a
complex formed between thrombin and its inhibitor
antithrombin III (20, 21). These studies showed
that native valve endocarditis due to miscellaneous
causative pathogens, in combination with throm-
boembolic events, elevated levels of both prothrom-
bin fragments and thrombin–antithrombin complex
as compared to endocarditis without thromboem-
bolic events or control patients. The authors’
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Fig. 4. See Fig. 2 caption.
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concluded that endocarditis and subsequent throm-
boembolic events were associated with impaired fib-
rinolysis and enhanced systemic activation of
coagulation (20, 21). The results of the present
study are partly in line with these observations. We
recorded elevated thrombin–antithrombin complex
at day 4 but no changes were observed in levels of
prothrombin fragments in endocarditis or throm-
boembolic patients as compared to controls. Fur-
thermore, ROC analyses suggested a predictability
of day 4 thrombin–antithrombin complex for endo-
carditis and thromboembolic events. However, dif-
ferences in study setups may explain these variable
results as we included only S. aureus as a causative
pathogen (20, 21).
Recent studies have shown that elevated D-dimer
at a level of 4.0–4.2 mg/L either on admission in
infective endocarditis (25) or within hours of blood
culture-positive infections (18) were associated with
increased in-hospital mortality. The mean D-dimer
levels observed in the present study were below
these proposed cut-off values and we could not
observe any differences in D-dimer levels between
MS-SAB patients with and without endocarditis or
thromboembolic events in our study.
Antithrombin III is a natural anticoagulant pro-
duced by th liver with potential anti-inflammatory
properties. Previous reports have shown that in sev-
ere infections, for example in critically ill sepsis
patients, antithrombin III levels are decreased and
antithrombin III has been evaluated as a potential
agent for sepsis treatment (17, 26, 36). In the pre-
sent study, levels of antithrombin III at day 4 were
significantly lower and at day 90 significantly higher
in patients with endocarditis as compared to con-
trols. Furthermore, in ROC analyses, both at the
day 4 and the day 90, the changes were predictable
for endocarditis but not for thromboembolic
events. The antithrombin III results of the present
study are comparable with those of a previous
observation for critically ill sepsis patients despite a
different patient population (17). Interestingly, we
could demonstrate that SAB in combination with
endocarditis is severe enough to suppress
antithrombin III levels among surviving MS-SAB
patients.
Fig. 5. See Fig. 2 caption.
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Fibrinogen and factor VIII are acute phase pro-
teins and natural procoagulants. Studies have
showed associations between severe sepsis and ele-
vated levels of fibrinogen and factor VIII (17, 19).
Moreover, increased concentrations of factor VIII
have been observed in patients with recurrent
thromboembolic events (37) and case reports have
presented elevated factor VIII levels secondary to
endocarditis (38). Factor VIII and fibrinogen levels
observed in this study were above baseline refer-
ences as a sign of upregulation of their production
in all SAB patients. However, there were no signifi-
cant differences between SAB patients with and
without complications. Therefore, these hemostasis
parameters are not predictive of endocarditis or
thromboembolic events in SAB.
APTT, an estimation of intrinsic and common
pathway coagulation activity, may be prolonged in
severe illnesses such as sepsis (17). The present
study observed prolonged APTT, compared to
baseline references, for the whole SAB study
population. Furthermore, at an early time-point,
SAB patients with endocarditis presented longer
APTT than controls. Anticoagulation may prolong
APTT. Thus, the question may be raised whether
the observation of prolonged APTT in this study
was due to use of anticoagulation. However, the
majority of patients with thromboembolic events
had anticoagulation therapy initiated in the first
week of SAB and no further prolongation of APTT
was observed. Thus, prolongation of APTT in
patients with endocarditis seems to be independent
of anticoagulation.
To further evaluate hemostasis parameter
changes in SAB, additional analyses were per-
formed with patients categorized according to ICU
vs non-ICU treatment, antibiotic mono- vs combi-
nation therapy and low (<2.0 mg/L) vs high
(>2.0 mg/L) D-dimer at day 4. The results from
these additional analyses were similar to the main
results using categorization according to endocardi-
tis or thromboembolic events. This strengthens the
Fig. 6. See Fig. 2 caption.
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conclusion that nonfatal MS-SAB patients receiving
proper clinical management present only marginal
hemostasis parameter changes.
Several studies connect MRSA bacteremia to
worse outcome and vancomycin, as compared to
beta-lactam antibiotics, as it is known to weaken
prognosis of MS-SAB (2, 39, 40). Furthermore, the
infectious disease specialist guidance has been
shown to enhance clinical management and
improve outcome (2, 4, 5). The present study pro-
vided formal infectious disease specialist bedside
consultation for each patient and included solely
MS-SAB cases. In consequence, all patients were
provided with proper antibiotic therapy from the
first day of MS-SAB diagnosis avoiding potential
effect of suboptimal medication. There were no
cases of septic shock, less than one-third of patients
required ICU treatment and deceased patients were
excluded. Hence, it is plausible to assume that
among surviving MS-SAB patients proper clinical
management may result in a rapid decline in the
S. aureus bacterial load resulting in a reduced
inflammation activity and lowered systemic coagu-
lation activation.
Most previous studies have reported hemostasis
parameters at a single time-point only. In addition,
the patient cohorts have been heterogeneous and
included critically ill patients irrespective of etiology
or patients with severe sepsis, bacteremia or endo-
carditis regardless of the causative pathogen (17–22,
25, 26). Our study provides a homogenous patient
cohort with respect to the primary condition (MS-
SAB) and follow-up until 3 months. Unlike previ-
ous studies, we used SAB patients as a control
group which further strengthens the homogeneity
of the patient cohort. The patient cohort here was
initially gathered for evaluation of the prognostic
impact of fluoroquinolone therapy on outcome in
SAB (34). Data for hemostasis parameter changes
in SAB were collected simultaneously.
The present study includes limitations that have to
be taken into account when interpreting the results.
Fig. 7. See Fig. 2 caption.
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First, the size of the study population was small,
however, large enough to observe changes in the
acute phase of certain hemostasis parameters when
comparing subjects with gender-age adjusted con-
trols. The main results were achieved also when
patients were categorized according to ICU treat-
ment or level of D-dimer which indicate that the
results are robust. Furthermore, modified power
analyses were made to estimate the reliability of the
patient cohort. Regarding the endocarditis group,
the mean observed power coefficient may be inter-
preted as satisfactory and together with the narrow
95% CIs it may be assumed that similar results
would be achieved with higher patient n-numbers as
well. However, the mean observed power coefficient
and the wide 95% CIs in the thromboembolic events
group suggests that the results have to be interpreted
with caution and larger studies are needed to further
assess the connection of hemostasis parameters to
thromboembolic events. Second, the study excluded
patients who deceased. The overall mortality in SAB
ranges from 15% to 30% and complications such as
endocarditis may further increase mortality (1–3).
This study is not able to give answers on changes in
hemostasis parameters in more severely ill patients
with a fatal outcome. Third, day 4 hemostasis
parameters were not influenced by anticoagulants (as
anticoagulant was not yet commenced at this time-
point) whereas days 10 and 90 hemostasis parame-
ters were influenced by anticoagulation. Fourth, the
patient cohort was gathered during years 1999–2002.
Although the clinical practice of SAB treatment con-
tinuously develops, the essential management of
SAB has not changed. The authors view that infec-
tious consultation in the present study has guaran-
teed recording of relevant data and enabled proper
management of SAB.
In conclusion, nonfatal MS-SAB patients with
endocarditis or thromboembolic events, as com-
pared to gender-age adjusted MS-SAB controls,
presented only few hemostasis parameter changes.
However, the observed early alterations in
antithrombin III, activated partial thromboplastin
time and thrombin–antithrombin complex, may
have some predictive value for endocarditis or
thromboembolic events. These results suggest that
proper clinical management in surviving MS-SAB
patients may result in decline of bacterial load,
reduced inflammation activity and lower systemic
coagulation activation.
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